DealForma review of Q1 2025 saw a surge in biopharma venture funding, with several companies securing $200 million+ rounds to advance differentiated therapies across metabolic, neurological, immunological, and ophthalmic diseases. Check out our research hubs.ly/Q03mRJVR0

Biopharma therapeutics and platforms IPO activity showed strong momentum in Q1 2025. Over $3 billion was raised through IPOs, PIPEs, and follow-on offerings, signaling a market rebound. Check out our research hubs.ly/Q03nH4tQ0

CNBC uses data from DealForma to report on Pfizer's and China's 3SBio's deal to license cancer drug. Watch the clip hubs.ly/Q03q0K_v0

AI drug discovery deals now feature nine‑figure upfronts and billion‑dollar milestones, with DealForma data showing a shift toward biologics, real‑world data, and broader pharma-AI partnerships. Read Nature's article here. hubs.ly/Q03qWg8q0

Our Q1 2025 review shows strong M&A and funding momentum across MedTech, especially in cardio, ortho, diabetes, ophthalmology, and digital health. Check out our research hubs.ly/Q03qWgSW0

Stifel’s ASCO 2025 recap, with DealForma data, highlights ADCs, bispecifics, evolving buyer strategies, and China’s rise in oncology licensing. Read it here hubs.ly/Q03r8Ls20

Cancer activity by TA was strong in Q1 2025, with significant R&D partnerships, acquisitions, and venture investments signaling continued growth. Read our research. hubs.ly/Q03s2kN70

Nature’s article on biotech’s shifting landscape cites DealForma data showing 2025 venture financing nearing $27B, with more money going to fewer, well-funded startups. Read it here hubs.ly/Q03sPS4y0

Your first look at biopharma-to-biopharma M&A through Q2. Capstan/AbbVie bumped up the median upfront M&A value. DealForma customers get reports full of charts on licensing and funding activity in Q2. Contact me if you are interested

M&A bankers had the busiest year in a while. Here's a look at H1 2025 M&A when we zoom out the database to broader life sciences, medtech, and CDMOs.

Biopharma licensing brought in $10 billion upfront in H1 2025. $7.7 billion of this was from 18 deals that had more than $100M upfront to challenge full-year 2024.

The first half of 2025 saw robust activity in the autoimmune space, with high-value R&D partnerships, strategic M&A deals, and strong venture funding. Check out our research hubs.ly/Q03wyCKj0

The Endpoints article highlights how biotech dealmaking has remained resilient in 2025 despite a tough fundraising climate, with a notable surge in licensing, M&A, and AI-driven agreements keeping activity high. Read it here hubs.ly/Q03wZFx40

Biotech dealmaking stayed strong in H1 2025 despite a tough market — M&A and AI-driven deals helped offset a dip in licensing. New charts via Dealforma in this Endpoints piece. hubs.ly/Q03w-66v0

If you missed John Knox's MedTech Summit, Chris Dokomajilar, CEO and Founder of DealForma presented the latest charts from the DealForma database tracking venture investments, licensing partnerships, and M&A in the medtech space. You can it at 2:47 mark. hubs.ly/Q03x6Lcb0

The Q2 2025 biopharma M&A landscape marked a strategic pivot toward targeted, mid-sized acquisitions, following a high-volume Q1. Check out our research hubs.ly/Q03zlC5g0

Our Q2 2025 review of biopharma venture funding reflected a clear flight to quality, with capital concentrating on clinically validated platforms and de-risked science. Check out our research hubs.ly/Q03Bbth00

Did you know that DealForma now includes unredacted contracts as part of our licensing, M&A, and supply deal coverage? You’ll see these unredacted documents linked directly from deal profiles where available - free to all DealForma customers.

Excited to share that J.P. Morgan’s latest Biopharma & Medtech Deal Reports are now live — powered by DealForma data. It's been an incredible 5+ years working with the J.P. Morgan Life Sciences team! hubs.ly/Q03BHfT-0

Q2 2025 marked a strong yet selective quarter for biopharma financing, with six major companies raising over $3 billion across IPOs and PIPEs. Check out our research hubs.ly/Q03CnGJZ0